Abion is focused on innovative drug development based on a number of the national research projects, including protein drugs, c-Met inhibitors, and nucleic acid therapeutics. In particular, the company has completed the development of the next-generation Interferon-beta, which is a multiple sclerosis drug, as well as anticancer drugs to treat stomach cancer and HPV-related cancer drugs to then proceed to clinical and nonclinical trials.